NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free MESO Stock Alerts $5.01 +0.32 (+6.82%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$4.60▼$5.1650-Day Range$1.82▼$6.5952-Week Range$1.61▼$10.24Volume500,146 shsAverage Volume1.92 million shsMarket Capitalization$571.49 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mesoblast alerts: Email Address Mesoblast MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside172.8% Upside$13.67 Price TargetShort InterestHealthy2.05% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.08 out of 5 starsMedical Sector538th out of 913 stocksBiological Products, Except Diagnostic Industry75th out of 134 stocks 3.1 Analyst's Opinion Consensus RatingMesoblast has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageMesoblast has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.05% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mesoblast has recently increased by 190.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MESO. Previous Next 2.9 News and Social Media Coverage News SentimentMesoblast has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Mesoblast this week, compared to 2 articles on an average week.Search Interest26 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows14 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.43% of the stock of Mesoblast is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.71) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Mesoblast Stock (NASDAQ:MESO)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More MESO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MESO Stock News HeadlinesApril 16, 2024 | msn.comInsiders are buying Mesoblast and these ASX sharesApril 13, 2024 | americanbankingnews.comMesoblast (NASDAQ:MESO) Shares Down 2.9% April 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 12, 2024 | americanbankingnews.comMesoblast Limited (NASDAQ:MESO) Given Consensus Rating of "Hold" by BrokeragesApril 10, 2024 | seekingalpha.comMesoblast Limited: Back From The DeadApril 5, 2024 | msn.comWhy is everyone talking about Mesoblast shares?April 4, 2024 | finance.yahoo.comSpinal Fusion Pipeline Report 2024, Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key CompaniesApril 3, 2024 | msn.comFed members back cutting rates this year, but need confidence inflation slowingApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 3, 2024 | investorplace.comFeeling Bold? 3 Aggressive Plays to 10X Your Returns by 2025April 3, 2024 | au.investing.comTop ASX Stocks for this MonthApril 2, 2024 | fool.com.auMesoblast share price dumps 10% as excitement simmers on FDA submissionApril 2, 2024 | au.investing.comWhat is next for Tesla stock after soft Q1 sales reportApril 1, 2024 | fool.com.auBlast off! Mesoblast share price surging 60%March 31, 2024 | fool.com.auTop ASX shares to buy in April 2024March 29, 2024 | finance.yahoo.comAohua receives Endoscopy Award at Healthcare Asia Medtech Awards 2024March 28, 2024 | morningstar.comMesoblast Ltd LWBMarch 27, 2024 | afr.comASX retreats ahead of CPI; Mesoblast soars 45pcMarch 27, 2024 | msn.comiBio, ImmunityBio, Mesoblast among healthcare moversMarch 26, 2024 | msn.comFDA Commentary Sends Biotech Soaring During Premarket HoursMarch 26, 2024 | marketwatch.comMesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L ApplicationMarch 26, 2024 | fool.com.auMesoblast share price rockets 36% on breaking FDA newsMarch 26, 2024 | afr.comASX slips as tech declines; Mesoblast soars 47pcMarch 26, 2024 | markets.businessinsider.comFDA Indicates Adequate Data For Mesoblast's Remestemcel-L BLA Submission In Children With SR-aGVHDMarch 25, 2024 | globenewswire.comUnited States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)March 20, 2024 | finance.yahoo.comMESO Jan 2025 0.500 callMarch 19, 2024 | finance.yahoo.comMESO Oct 2024 2.000 callSee More Headlines Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/30/2023Today4/18/2024Next Earnings (Estimated)5/23/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees83Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$34.00 Low Stock Price Target$3.00 Potential Upside/Downside+172.8%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.21 Current Ratio2.71 Quick RatioN/A Sales & Book Value Annual Sales$7.50 million Price / Sales76.20 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book0.81Miscellaneous Outstanding Shares114,070,000Free Float92,626,000Market Cap$571.49 million OptionableOptionable Beta3.60 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $738.74kDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $625.46kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATEValnevaNASDAQ:VALNExscientiaNASDAQ:EXAINovavaxNASDAQ:NVAXAlectorNASDAQ:ALECView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 3,500 shares on 2/15/2024Ownership: 0.000%Affinity Asset Advisors LLCSold 400,000 shares on 2/13/2024Ownership: 0.000%Simplex Trading LLCSold 2,600 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions MESO Stock Analysis - Frequently Asked Questions Should I buy or sell Mesoblast stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares. View MESO analyst ratings or view top-rated stocks. What is Mesoblast's stock price target for 2024? 6 brokers have issued 1 year price targets for Mesoblast's shares. Their MESO share price targets range from $3.00 to $34.00. On average, they anticipate the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 172.8% from the stock's current price. View analysts price targets for MESO or view top-rated stocks among Wall Street analysts. How have MESO shares performed in 2024? Mesoblast's stock was trading at $2.20 at the beginning of the year. Since then, MESO stock has increased by 127.7% and is now trading at $5.01. View the best growth stocks for 2024 here. Are investors shorting Mesoblast? Mesoblast saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,340,000 shares, an increase of 190.1% from the March 15th total of 806,500 shares. Based on an average daily trading volume, of 2,140,000 shares, the short-interest ratio is currently 1.1 days. View Mesoblast's Short Interest. When is Mesoblast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our MESO earnings forecast. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) announced its quarterly earnings data on Wednesday, August, 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. The business had revenue of $2.14 million for the quarter, compared to analysts' expectations of $2 million. When did Mesoblast's stock split? Mesoblast's stock reverse split on the morning of Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV). When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MESO) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressOptions trading has suddenly become more reliable.Eagle Publishing[BUY ALERT] Our #1 A.I. Stock for AprilBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.